Affiliated Treatment Facilities
Moores Cancer Center
3855 Health Sciences Drive
La Jolla, CA 92093
01. Doctor Overview
Dr. Joel M. Baumgartner is a surgical oncologist who specializes in melanoma and cancers of the gastrointestinal tract, including peritoneal mesothelioma. Dr. Baumgartner joined the staff at UC San Diego Health-Moores Cancer Center in August 2012. This is the only National Cancer Institute-designated Comprehensive Cancer Center in the San Diego region. In addition to his medical practice, Dr. Baumgartner has continued to perform clinical research, helping to develop and conduct various clinical trials.
Dr. Baumgartner learned how to treat patients with hyperthermic intraperitoneal chemotherapy (HIPEC) while completing his fellowship at the University of Pittsburgh, one of the highest volume HIPEC centers worldwide. He spent two years here, getting ample experience with the malignant peritoneal mesothelioma treatment. Through this experience and more, Dr. Baumgartner has been able to share his expertise through various publications.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Surgical Oncology
Other Interests & Specialties: General surgery, gastrointestinal tract cancers, tumors that have metastasized to the abdomen, hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with surgical resection, melanoma, lymph node biopsies and lymph node dissections.
Certifications, Awards & Accolades: American Board of Surgery Certification in Surgery, Society of Surgical Oncology member, American Society of Clinical Oncology member, American Association for Cancer Research and the American College of Surgeons associate member
Education & Experience:
- Medical Degree from Indiana University School of Medicine
- Residency at University of Colorado
- Fellowship at University of Pittsburgh Medical Center
Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma. Journal of Gastrointestinal Surgery. August 2018. doi: 10.1007/s11605-018-3918-3
Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. Annals of Surgical Oncology. August 2018;25(8):2400-2408. doi: 10.1245/s10434-018-6561-z
A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology. May 2016;23(5):1609-1617. doi: 10.1245/s10434-015-5012-3
Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery. Annals of Surgical Oncology. May 2016;23(5):1609-1617. doi: 10.1245/s10434-015-4958-5